K

Krystal Biotech, Inc. Common Stock

XNAS · Laboratory Analytical Instruments · S&P 500

$339.22

-$16.38 (-4.61%) today

Open $355.60 High $360.98 Low $338.85 Vol 338K Avg $344.24

Related Stocks

Find similar stocks by technical condition — S&P 500 universe

Symbol Company Name Exchange Currency Category
LIMN Liminatus Pharma, Inc. Class A Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CMPX Compass Therapeutics, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
EXOZ eXoZymes Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
PHGE BiomX Inc. XASE USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SANA Sana Biotechnology, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SGMO Sangamo Therapeutics, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
PCVX Vaxcyte, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
TECH Bio-Techne Corp. XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CELZ Creative Medical Technology Holdings, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
MGTX MeiraGTx Holdings plc Ordinary Shares XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

52-week price range

$130.50 $382.54

Price is 159.9% above its 52-week low and 11.3% below its 52-week high. Trading in the upper half of its annual range — closer to the peak than the base.

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

  • Primary Exchange: XNAS
  • Market Cap: 8028599721.5
  • Address:
  • Category: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
  • Total Employees: 295
  • Listing Date: 2017-09-20